Interpace Biosciences Announces First Quarter 2020 Financial and Business Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Interpace Biosciences (IDXG) Misses Q1 EPS by $1.09, Revenues Beat
June 25, 2020 5:03 PM EDTInterpace Biosciences (NASDAQ: IDXG) reported Q1 EPS of ($2.31), $1.09 worse than the analyst estimate of ($1.22). Revenue for the quarter came in at $9.2 million versus the consensus estimate of $8.93 million.
Net Revenue for the first quarter of 2020 was $9.2 million, an increase of 53% from the prior year first quarter, which did not include Pharma services revenues.Gross Profit was 34% as compared to 56% in the first quarter of 2019; this decrease was due principally to the lower margins associated with Pharma services in 2020.Loss from Continuing Operations was $(6.2) million as compared to $(3.4)... More